Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 23Terminated 7Recruiting 3Unknown 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 4Primary Myelofibrosis 2Myeloproliferative Disorders 2Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 10fludarabine phosphate 9Rituximab 9Cytarabine 9Peripheral Blood Stem Cell Transplantation 8Methotrexate 8Filgrastim 6Cyclosporine 6fludarabine 5Radiotherapy 5Busulfan 5Tacrolimus 4Mycophenolic Acid 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4Bendamustine Hydrochloride 4venetoclax 3duvelisib 3Whole-Body Irradiation 3Sirolimus 3Melphalan 3Antilymphocyte Serum 3Prednisone 2N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 2Mitoxantrone 2Lenalidomide 2Interferon-alpha 2Drug Therapy 2Clofarabine 2Arsenic Trioxide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia × Decitabine × Clear all
NCT05740449 2024-06-21

HEM-iSMART A

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡